The changing landscape of the vulnerable plaque: a call for fine-tuning of preclinical models.

Atherosclerotic plaque Disease modelling Phenotypic switch Plaque cells Vulnerable plaque

Journal

Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615

Informations de publication

Date de publication:
12 2021
Historique:
received: 07 07 2021
revised: 08 09 2021
accepted: 28 09 2021
pubmed: 5 10 2021
medline: 26 3 2022
entrez: 4 10 2021
Statut: ppublish

Résumé

For decades, the pathological definition of the vulnerable plaque led to invaluable insights into the mechanisms that underlie myocardial infarction and stroke. Beyond plaque rupture, other mechanisms, such as erosion, may elicit thrombotic events underlining the complexity and diversity of the atherosclerotic disease. Novel insights, based on single-cell transcriptomics and other "omics" methods, provide tremendous opportunities in the ongoing search for cell-specific determinants that will fine-tune the description of the thrombosis prone lesion. It coincides with an increasing awareness that knowledge on lesion characteristics, cell plasticity and clinical presentation of ischemic cardiovascular events have shifted over the past decades. This shift correlates with an observed changes of cell composition towards phenotypical stabilizing of human plaques. These stabilization features and mechanisms are directly mediated by the cells present in plaques and can be mimicked in vitro via primary plaque cells derived from human atherosclerotic tissues. In addition, the rapidly evolving of sequencing technologies identify many candidate genes and molecular mechanisms that may influence the risk of developing an atherosclerotic thrombotic event - which bring the next challenge in sharp focus: how to translate these cell-specific insights into tangible functional and translational discoveries?

Identifiants

pubmed: 34607015
pii: S1537-1891(21)00096-3
doi: 10.1016/j.vph.2021.106924
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

106924

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Michele F Buono (MF)

Laboratory of Experimental Cardiology, University Medical Center Utrecht, the Netherlands.

Lotte Slenders (L)

Central Diagnostics Laboratory, University Medical Center Utrecht, Utrecht, the Netherlands.

Marian Wesseling (M)

Central Diagnostics Laboratory, University Medical Center Utrecht, Utrecht, the Netherlands.

Robin J G Hartman (RJG)

Laboratory of Experimental Cardiology, University Medical Center Utrecht, the Netherlands.

Claudia Monaco (C)

Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.

Hester M den Ruijter (HM)

Laboratory of Experimental Cardiology, University Medical Center Utrecht, the Netherlands.

Gerard Pasterkamp (G)

Central Diagnostics Laboratory, University Medical Center Utrecht, Utrecht, the Netherlands.

Michal Mokry (M)

Laboratory of Experimental Cardiology, University Medical Center Utrecht, the Netherlands; Central Diagnostics Laboratory, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address: M.Mokry@umcutrecht.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH